Patents by Inventor Karen Curd

Karen Curd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of cancer using hypoxia activated prodrugs
    Patent number: 8946275
    Abstract: Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anti-cancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated prodrug may be completed prior to beginning administration of the other anticancer agent or radiation therapy.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: February 3, 2015
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Stewart Kroll, Mark Matteucci, Charles P. Hart, Jian-Xin Duan, Karen Curd
  • METHODS FOR TREATING CANCER
    Publication number: 20140171389
    Abstract: Administration of TH-302 or another hypoxia activated prodrug in combination with a pharmacological agent that down-regulates or inhibits homology directed repair (HDR) is useful for treating cancer.
    Type: Application
    Filed: March 30, 2012
    Publication date: June 19, 2014
    Applicant: THRESHOLD PHARMACEUTICALS, INC.
    Inventor: Karen Curd
  • ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS AND ANTIANGIOGENIC AGENTS FOR THE TREATMENT OF CANCER
    Publication number: 20140010805
    Abstract: Administration of a hypoxia activated prodrug in combination with an antiangiogenic agent is useful for treating cancer.
    Type: Application
    Filed: July 11, 2011
    Publication date: January 9, 2014
    Inventor: Karen Curd
  • TREATMENT OF BLOOD CANCER
    Publication number: 20130296273
    Abstract: Hypoxia activated prodrugs, such as, e.g., TH-281, TH-302, and TH-308, are useful for the treatment of various blood cancers, such as acute leukemias, chronic leukemias, MDS, MF, and multiple myeloma.
    Type: Application
    Filed: June 27, 2011
    Publication date: November 7, 2013
    Inventor: Karen Curd
  • Treatment of Cancer Using Hypoxia Activated Prodrugs
    Publication number: 20130202716
    Abstract: Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anti-cancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated prodrug may be completed prior to beginning administration of the other anticancer agent or radiation therapy.
    Type: Application
    Filed: October 21, 2009
    Publication date: August 8, 2013
    Inventors: Stewart Kroll, Mark Matteucci, Charles P. Hart, Jian-Xin Duan, Karen Curd